Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MESO with free AI briefings, catalyst countdowns, and dilution alerts.

MESO · MESOBLAST LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$102.9M Cash on Hand
28.2mo Cash Runway
Follow MESO by email Get an email when MESO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MESO, unsubscribe in one click. Privacy

📣 What MESO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Rexlemestrocel-L Degenerative Disc Disease Phase 3 · NCT06325566 Active not recruiting
Remestemcel-L-Rknd GVHD - Graft-Versus-Host Disease Phase 3 · NCT07568535 Not yet recruiting
Remestemcel-L Mesenchymal Stromal Cells Phase 3 · NCT04371393 Terminated
Infusion of one MPC expanded cord unit and one… Acute Myelogenous Leukemia Phase 3 · NCT01854567 Completed
Infusion of two unexpanded cord blood units. Acute Myelogenous Leukemia Phase 3 · NCT01854567 Completed
PROCHYMAL adult human mesenchymal stem cells Crohn's Disease Phase 3 · NCT00543374 Completed
NeoFuse Cervical Degenerative Disc Disease Phase 1/2 · NCT01106417 Completed
Stem Cell Degenerative Disc Disease Phase 1/2 · NCT00810212 Withdrawn
Lumbar Interbody Fusion with Autograft Degenerative Disc Disease Phase 2 · NCT00996073 Completed
Allogeneic Mesenchymal Precursor Cells Rheumatoid Arthritis Phase 2 · NCT01851070 Completed
Autologous Expanded Mesenchymal Stem Cells… Graft Versus Host Disease Phase 2 · NCT00081055 Withdrawn
Chondrogen Recovery Following Partial Medial Meniscectomy Phase 1/2 · NCT00702741 Completed
Hyaluronic Acid Recovery Following Partial Medial Meniscectomy Phase 1/2 · NCT00225095 Completed
Mesenchymal Precursor Cells (MPC) 12.5 M Acute Myocardial Infarction Phase 2 · NCT01781390 Completed
Mesenchymal Precursor Cells (MPC) 25 M Acute Myocardial Infarction Phase 2 · NCT01781390 Completed
Mesenchymal Precursor Cells (MPCs) Type 2 Diabetes Phase 1/2 · NCT01576328 Completed

Also used in these trials (approved or third-party drugs, not MESO's own candidates): Mycophenolate Mofetil, Prednisone, Tacrolimus Extended-Release, Busulfan, Cyclophosphamide, Cyclosporine, Methotrexate, Hydrocortisone, Diphenhydramine Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MESO holds $102.9M in cash and short-term investments and burns about $11M/quarter from operations, an estimated runway of 28.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MESO files for a raise →

👥 Who Owns MESO

Insiders 8.9% Institutions (96 holders) 3.4% Public and other holders 87.7%
HolderTypeShares% of sharesAs of
Silviu Itescu
CEO and Managing Director, Director
Insider 78,958,928 6.09% 2026-03-18
Gregory George
Director, 10% owner
Insider 33,910,962 2.61% 2026-04-09
Eric Allen Rose
Chief Medical Officer,Director, Director
Insider 714,720 0.06% 2026-03-18
Jane Catherine Bell
Director
Insider 622,492 0.05% 2026-03-18
Philip R. Krause
Director
Insider 287,500 0.02% 2026-03-18
William Murray Burns
Director
Insider 226,250 0.02% 2026-03-18
Philip James Facchina
Director
Insider 123,220 0.01% 2026-03-18
Lynette Elizabeth Cobley
Director
Insider 63,000 0.00% 2026-03-18

Share count 1,296,862,776 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MESO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MESO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.